Navigation Links
Senetek PLC Reports First Quarter 2008 Financial Results
Date:5/15/2008

Agreement in Principle Reached to Terminate Marketing Agreement with Triax

Aesthetics, LLC for Pyratine-6(TM) on Most Favorable Terms

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced financial results for the quarter ended March 31, 2008 and an agreement in principle to terminate its marketing agreement with Triax Aesthetics, LLC ("Triax") for Pyratine-6(TM) on most favorable terms.

Revenue for the quarter ended March 31, 2008 was $441,000, compared with $25,308,000 reported in the first quarter of 2007. Revenues for the first quarter of 2007 included $24,750,000 recognized in conjunction with the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.

Net loss for the quarter ended March 31, 2008 totaled $1,757,000, a loss of $0.23 per share compared to a net income of $21,733,000 or $2.85 per share in the first quarter of 2007. Net loss for the quarter ended March 31, 2008 included $926,000 of sales and marketing fee expense to Triax. Net income for the quarter ended March 31, 2007 included the effect of the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc. and $1,320,000 from settlement of claims against a professional services provider for past performance related matters.

The Company has reached an agreement in principle, subject to receipt of certain documentation and information, to terminate its marketing agreement with Triax for Pyratine-6(TM) on most favorable terms. These terms would include the return of $1,125,000 in cash from Triax and a service provider, return of all intellectual property, product inventory and promotional materials, access and ownership of all accounts opened, a non-competition agreement from Triax and certain related parties prohibiting them from selling any topical cosmetic non monograph products used for antiaging purpose and/or in connection with acne rosacea for a period of two years, along with rights to utilization of the "Triax Aesthetics" name in conjunction with the sales of existing packaged product inventory. The termination agreement is expected to be finalized shortly.

The Company will announce the date and time of a teleconference call for investors when the agreement to terminate its marketing agreement with Triax is finalized.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces Appointments of Key Personnel
2. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
3. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
4. China Biologic Products Reports First Quarter 2008 Results
5. Escalon(R) Reports Third Quarter Fiscal 2008 Results
6. Cadus Reports First Quarter 2008 Results
7. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
8. SPO Medical Reports First Quarter 2008 Results
9. Nile Therapeutics Reports 2008 First Quarter Financial Results
10. Derma Sciences Reports First Quarter 2008 Results
11. NeurogesX Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
Breaking Biology Technology:
(Date:8/15/2017)... ivWatch LLC , a medical device company focused on improving the ... its ISO 13485 Certification, the global standard for medical device quality ... ... device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):